Skip to content

Return on assets at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
8.1%+2.5pp
Gilead Sciences logo
Gilead SciencesGILD
16.4%+5.8pp
Kyverna Therapeutics, Inc. logo
Kyverna Therapeutics, Inc.KYTX
-60.4%+32.8pp
Allogene Therapeutics logo
Allogene TherapeuticsALLO
-38.4%-5.5pp
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
-60.4%-10.7pp
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-179.8%+218pp

Other financials

Income statement

See full
Revenue-
Operating income-$24.4M-10.2%
Net income-$23.5M-15.8%
EPS (diluted)-$0.95-14.5%

Balance sheet

See full
Cash & equivalents$21.4M-30.6%
Total debt$10.3M-26.7%
Total equity$87.8M-48.0%
Total assets$106.0M-44.6%

Cash flow

See full
Operating cash flow-$21.0M-5.6%
CapEx$242.0K-52.6%
Free cash flow-$21.2M-4.1%

Valuation

See full
Market cap$429.03M+1,015%
Enterprise value$417.88M+1,832%

Profitability

See full
Operating margin-83.9%
Net margin-79.3%

Returns & leverage

See full
Return on equity-67.9%
Debt / equity0.1×0.0×
Current ratio8.2×-5.8×

Where this comes from

Calculated from Artiva Biotherapeutics, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Artiva Biotherapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Artiva Biotherapeutics, Inc.'s return on assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Artiva Biotherapeutics, Inc.'s return on assets?
Artiva Biotherapeutics, Inc. (ARTV) reported return on assets of -58.6% in Q1 2026.
What does return on assets mean?
Trailing-twelve-month net income divided by average total assets. Measures how efficiently the asset base generates profit, independent of how those assets are financed. Computed as net income over average total assets — note this is OpenCapital's standard definition and may differ from data vendors that use alternative numerators.